The Meningococcal Disease Vaccine Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Meningococcal Disease Vaccine Market?
The global market for the meningococcal disease vaccine has seen significant growth in recent years. The market size is projected to increase from $2.37 billion in 2024 to $2.62 billion in 2025, with a compound annual growth rate (CAGR) of 10.4%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Meningococcal Disease Vaccine Industry?
The Global Meningococcal Disease Vaccine Market is projected to reach $3.83 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.0%.
Download Your Free Sample of the 2025 Meningococcal Disease Vaccine Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Meningococcal Disease Vaccine Market?
The key drivers in the meningococcal disease vaccine market are:
• Rising awareness of preventive healthcare
• Expansion of target age groups for vaccination
• Entry of new players in the market
• Stockpiling of vaccines by governments and health agencies in case of outbreaks.
Global Market Segmentation: Identifying Major Meningococcal Disease Vaccine Industry Segments
The meningococcal disease vaccine market covered in this report is segmented –
1) By Vaccine Type: Conjugate Vaccines, Polysaccharide Vaccines, Recombinant Vaccines, Live Attenuated Vaccines
2) By Age Group: Infants, Children, Adults, Older Adults
3) By Indication: Preventive Vaccination, Post-Exposure Prophylaxis, Travel-Related Vaccination, Outbreak Response
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Pre-order the 2025 Meningococcal Disease Vaccine Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Meningococcal Disease Vaccine Market?
The key trends in the meningococcal disease vaccine market are:
• The meningococcal disease vaccine market is trending towards advancements in vaccine technology.
• The development of multivalent, conjugate, and protein-based vaccines is an emerging trend.
• The impact of global travel and migration trends on the vaccine market is becoming more significant.
• There is an increasing focus on research and development for mRNA and innovation in thermostable formulations.
Who Are the Top Competitors & Leading Players in the Meningococcal Disease Vaccine Market?
Major players in the meningococcal disease vaccine market are:
• Pfizer Inc.
• Merck & Co. Inc.
• Sanofi SA
• Novartis AG
• GlaxoSmithKline plc
• Hualan Biological Engineering Inc.
• Beijing Tiantan Biological Products Corporation Limited
• Serum Institute of India Pvt. Ltd.
• Walvax Biotechnology Co. Ltd.
• Incepta Pharmaceuticals Ltd.
• CanSino Biologics Inc.
• EuBiologics Co. Ltd.
• Biovac Institute
• Shantha Biotech
• Bio-Manguinhos
• Biomed Pvt. Ltd.
• Chengdu Kanghua Biological Products Co. Ltd.
• Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.
• Finlay Institute of Vaccines
• Immunopreparat.
Regional Dominance: Which Area Leads the Global Meningococcal Disease Vaccine Market?
North America was the largest region in the meningococcal disease vaccine market in 2024
